CalciMedica, Inc. Common Stock (CALC) Stock Price

CALCStock
$1.04−93.60%52W
Market Cap$7.10M
P/E—
PEG Ratio—
Div yield—
Beta0.82

CALC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-76.36%
Price vs S&P 500 (4W)-42.76%
VGM Score10.23

CALC Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$1.45-$2.25-55.17%(-$0.80)
Q1 2026-$1.40$1.50+207.14%(+$2.90)
Q4 2025-$2.06-$3.45-67.27%(-$1.39)
Q3 2025-$2.06-$2.60-26.06%(-$0.54)
Q2 2025-$1.75-$2.00-14.29%(-$0.25)

CALC Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.10
4.10
4.00
4.10

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
CALCCalciMedica, Inc. Common Stock
——F————$1.04
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About CalciMedica, Inc. Common Stock

CalciMedica is a clinical-stage biopharmaceutical company developing treatments for serious inflammatory and immune-mediated diseases. Its lead candidate, Auxora, is a CRAC channel inhibitor designed to reduce inflammation and cellular damage in organs including the pancreas, lungs, and kidneys. Preclinical studies suggest potential therapeutic benefit for conditions driven by inflammatory and immune dysfunction.